Why the study?
Do supratherapeutic doses of ebastine increase the QTc interval compared to terfenadine and placebo in subjects?
Do supratherapeutic doses of ebastine increase the QTc interval compared to terfenadine and placebo in subjects?
Supratherapeutic doses of ebastine up to 100 mg/day do not cause clinically relevant changes in the QTc interval, unlike terfenadine.
No takes yet. Share an insight, caveat, or question.
Supratherapeutic ebastine shows low QTc risk unlike terfenadine; confirms differential cardiac safety in this RCT.
Gillen et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: